Neurochemistry of drug action: Insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction

Annals of the New York Academy of Sciences

Volumn 1187, Issue , 2010, Pages 148-171

  Licata, Stephanie C ^a   Renshaw, Perry F ^b  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Brain imaging; Drug abuse; Human; Proton magnetic resonance spectroscopy

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID; ALCOHOL; AMPHETAMINE; BIOLOGICAL MARKER; BRAIN AMINE; BRAIN PROTEIN; CANNABIS; CHOLINE; COCAINE; CREATINE; DEXAMPHETAMINE; DIAMORPHINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; METHADONE; METHAMPHETAMINE; MORPHINE; N ACETYLASPARTIC ACID; NICOTINE; TOLUENE;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ALCOHOLISM; AMINO ACID BRAIN LEVEL; BASAL GANGLION; BRAIN METABOLISM; CINGULATE GYRUS; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; ENERGY METABOLISM; HIPPOCAMPUS; HUMAN; INFLAMMATION; LIVER INJURY; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OCCIPITAL CORTEX; PREFRONTAL CORTEX; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; RESPIRATION DEPRESSION; REVIEW; THALAMUS; TOBACCO DEPENDENCE; VIRUS INFECTION; WHITE MATTER;

EID: 77949302267     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05143.x     Document Type: Review

References (243)

1. Bartsch, A.J., G. Homola, A. Biller, et al. 2007. Manifestations of early brain recovery associated with abstinence from alcoholism. Brain 130: 36-47.
2. Bendszus, M., H.G. Weijers, G. Wiesbeck, et al. 2001. Sequential MR imaging and proton MR spectroscopy in patients who underwent recent detoxification for chronic alcoholism: correlation with clinical and neuropsychological data. AJNR Am. J. Neuroradiol. 22: 1926-1932.
3. Durazzo, T.C., S. Gazdzinski, J.C. Rothlind, et al. 2006. Brain metabolite concentrations and neurocognition during short-termrecovery from alcohol dependence: preliminary evidence of the effects of concurrent chronic cigarette smoking. Alcohol Clin. Exp. Res. 30: 539-551.
4. Ende, G., H.Welzel, S. Walter, et al. 2005. Monitoring the effects of chronic alcohol consumption and abstinence on brain metabolism: a longitudinal proton magnetic resonance spectroscopy study. Biol. Psychiatry 58: 974-980.
5. Parks, M.H., B.M. Dawant, W.R. Riddle, et al. 2002. Longitudinal brain metabolic characterization of chronic alcoholics with proton magnetic resonance spectroscopy. Alcohol Clin. Exp. Res. 26: 1368-1380.
6. Streeter, C.C., J. Hennen, Y. Ke, et al. 2005. Prefrontal GABA levels in cocaine-dependent subjects increase with pramipexole and venlafazine treatment. Psychopharmacology 182: 516-526.
7. Meyerhoff,D.J. & T.C.Durazzo. 2008. Proton magnetic resonance spectroscopy in alcohol use disorders: a potential new endophenotype. Alcohol Clin. Exp. Res. 32: 1146-1158.
8. Moore, C.M., B.B. Frederick & P.F. Renshaw. 1999. Brain biochemistry using magnetic resonance spectroscopy: relevance to psychiatric illness in the elderly. J. Geriatr. Psychiatry Neurol. 12: 107-117.
9. Moffett, J.R., B. Ross, P. Arun, et al. 2007. NAcetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81: 89-131.
10. Pouwels, P.J. & J. Frahm. 1997. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed. 10: 73-78.
11. Tallan, H.H., S. Moore & W.H. Stein. 1956. N-Acetyl- L-aspartic acid in brain. J. Biol. Chem. 219: 257-264.
12. Pouwels, P.J. & J. Frahm. 1998. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 39: 53-60.
13. Inglese, M., H. Rusinek, I.C. George, et al. 2008. Global average gray and white matter N-acetylaspartate concentration in the human brain. Neuroimage 41: 270-276.
14. Nadler, J.V. & J.R. Cooper. 1972. N-acetyl-aspartic acid content of human neural tumours and bovine peripheral nervous tissues. J. Neurochem. 19: 313-319.
15. Brooks, W.M., S.D. Friedman & C. Gasparovic. 2001. Magnetic resonance spectroscopy in traumatic brain injury. J. Head Trauma Rehabil. 16: 149-164.
16. Chen, J.G., H.C. Charles, D.P. Barboriak, et al. 2000. Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta. Neurol. Scand. Suppl. 176: 20-26.
17. Demougeot, C., C. Marie, M. Giroud, et al. 2004. N-acetylaspartate: a literature review of animal research on brain ischemia. J. Neurochem. 90: 776-783.
18. Simone, I.L., C. Tortorella & F. Federico. 1999. The contribution of (1)H-magnetic resonance spectroscopy in defining the pathophysiology of multiple sclerosis. Ital. J. Neurol. Sci. 20: S241-S245.
19. Li, S.-J., Y.Wang, J.Pankiewicz, et al. 1999.Neurochemical adaptation to cocaine abuse: reduction of N-acetyl aspartate in thalamus of human cocaine abusers. Biol. Psychiatry 45: 1481-1487.
20. Stork, C. & P.F. Renshaw. 2005. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 10: 900-919.
21. Bonavita, S., F. Di Salle & G. Tedeschi. 1999. Proton MRS in neurological disorders. Eur. J. Radiol. 30: 125-131.
22. Frey, B.N., J.A. Stanley, F.G.Nery, et al. 2007. Abnormal cellular energy and phopholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individualswith bipolar disorder: an in vivo 1HMRS study. Bipolar Disord. 9(Suppl. 1): 119-127.
23. Yerli, H., A.M. Aǧildere, O. Ozen, et al. 2007. Evaluation of cerebral glioma grade by using normal side creatine as an internal reference in multi-voxel 1H-MR spectroscopy. Diagn. Interv. Radiol. 13: 3-9.
24. King, K.G., L. Glodzik, S. Liu, et al. 2008. Anteroposterior hippocampal metabolic heterogeneity: three-dimensional multivoxel proton 1H MR spectroscopic imaging-initial findings. Radiology 249: 242-250.
25. Miller, B.L. 1991. A review of chemical issues in 1H NRM spectroscopy: N-acetyl-l aspartate, creatine and choline. NMR Biomed. 4: 47-52.
26. Gonzalez-Toledo, E., R.E. Kelley & A. Minager. 2006. Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis. Neurol. Res. 28: 280-283.
27. Nakanishi, T., R.J. Turner&M.B. Burg. 1989. Osmoregulatory changes inmyo-inositol transport by renal cells. Proc. Natl. Acad. Sci. USA 86: 6002-6006. (Pubitemid 19217574)
28. Ross, B.D. 1991. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed. 4: 59-63.
29. Berridge, M.J. & R.F. Irvine. 1989. Inositol phosphates and cell signaling. Nature 341: 197-205.
30. Kim, H., B.M. McGrath & P.H. Silverstone. 2005. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle to psychiatric disorders-focus on magnetic resonance spectroscopy (MRS) studies. Hum. Psychopharmacol. 20: 309-326.
31. Brand, A., C. Richter-Landsberg & D. Leibfritz. 1993. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci. 15: 289-298.
32. Behar, K.L. & D.L. Rothman. 2001. In vivo nuclear magnetic resonance studies of glutamate-gammaaminobutyric acid-glutamine cycling in rodent and human cortex: the central role of glutamine. J. Nutr. 131: 2498S-2504S.
33. Mullins, P.G., H. Chen, J. Xu, et al. 2008. Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn. Reson. Med. 60: 964-969.
34. Behar, K.L., D.L. Rothman, D.D. Spencer, et al. 1994. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn. Reson. Med. 32: 294-302.
35. Kish, S.J., T.L. Perry & S.Hansen. 1979. Regional distribution of homocarnosine, homocarnosine-carnosine synthetase and homocarnosinase in human brain. J. Neurochem. 32: 1629-1636.
36. Gass, J.T. & M.F. Olive. 2008. Glutamatergic substrates of drug addiction and alcoholism. Biochem. Pharmacol. 75: 218-265.
37. Torregrossa, M.M. & P.W. Kalivas. 2008. Microdialysis and the neurochemistry of addiction. Pharmacol. Biochem. Behav. 90: 261-272.
38. Quinton, M.S. & B.K. Yamamoto. 2006. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J. 18: E337-E347.
39. Ricaurte, G.A. & U.D. McCann. 1992. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann. N. Y. Acad. Sci. 648: 371-382.
40. Ernst, T. & L. Chang. 2008. Adaptation of brain glutamate plus glutamine during abstinence from chronic methamphetamine use. J. Neuroimmune Pharmacol. 3: 165-172.
41. Cadet, J.L., I.N. Krasnova, S. Jayanthi, et al. 2007. Neurotoxicity of substituted amphetamines:molecular and cellular mechanisms. Neurotox. Res. 11: 183-202.
42. Lundqvist,T. 2005.Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol. Biochem. Behav. 81: 319-330.
43. McGrath, B.M., R. McKay, S. Dave, et al. 2008. Acute dextro-amphetamine administration does not alter brainmyo-inositol levels in humans and animals: MRS investigations at 3 and 18.8 T. Neurosci. Res. 61: 351-359.
44. Silverstone, P.H., T. O'Donnell, M. Ulrich, et al. 2002. Dextro amphetamine increases phosphoinositol cycle activity in volunteers: an MRS study.Hum. Psychopharmacol. 17: 425-429.
45. Berridge, M.J., C.P. Downes & M.R. Hanley. 1982. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 206: 587-595.
46. Berridge, M.J., C.P.Downes& M.R.Hanley. 1989.Neural and developmental actions of lithium: a unifying hypothesis. Cell 59: 411-419.
47. Kim, H., R.B. Thompson, C.C. Hanstock, et al. 2005. Variability of metabolite yield using STEAM or PRESS sequences in vivo at 3.0 T, illustrated with myo-inositol. Magn. Reson. Med. 53: 760-769.
48. Melega, W.P., J. Quintana, M.J. Raleigh, et al. 1996. 6-[18F]fluoro-L-DOPA-PET studies show partial reversibility of long-termeffects of chronic amphetamine in monkeys. Synapse 22: 63-69.
49. Ridley, R.M., H.F. Baker, F. Owen, et al. 1982. Behavioural and biochemical effects of chronic amphetamine treatment in the vervetmonkey. Psychopharmacology 78: 245-251.
50. Steranka, L.R. & E. Sanders-Bush. 1980. Long-term effects of continuous exposure to amphetamine on brain dopamine concentration and synaptosomal uptake in mice. Eur. J. Pharmacol. 65: 439-443.
51. Wagner,G.C., G.A. Ricaurte, C.E. Johanson, et al. 1980. Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate.Neurology 30: 547-550.
52. McCann, U.D., D.F. Wong, F. Yokoi, et al. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence frompositron emission tomography studieswith [11C]WIN-35,428. J. Neurosci. 18: 8417-8422.
53. Volkow, N.D., L. Chang, G.J. Wang, et al. 2001. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158: 377-382.
54. Sekine, Y., Y. Ouchi, N. Takei, et al. 2006. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry 63: 90-100.
55. London, E.D., S.L. Simon, S.M. Berman, et al. 2004. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch. Gen. Psychiatry 61: 73-84.
56. Volkow, N.D., L. Chang, G.J.Wang, et al. 2001. Higher cortical and lower subcorticalmetabolism in detoxified methamphetamine abusers.Am. J. Psychiatry 158: 383-389.
57. Wang, G.J., N.D. Volkow, L. Chang, et al. 2004. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am. J. Psychiatry 161: 242-248.
58. Chang, L., C. Cloak, K. Patterson, et al. 2005. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol. Psychiatry 57: 967-974.
59. Chung, A., I.K. Lyoo, S.J. Kim, et al. 2007. Decreased frontal white-matter integrity in abstinent methamphetamine abusers. Int. J. Neuropsychopharmacol. 10: 765-775.
60. Kim, S.J., I.K. Lyoo, J. Hwang, et al. 2006. Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers. Int. J. Neuropsychopharmacol. 9: 221-228.
61. Thompson, P.M., K.M.Hayashi, S.L. Simon, et al. 2004. Structural abnormalities in the brains of human subjects who usemethamphetamine. J.Neurosci. 24: 6028-6036.
62. Ernst, T., L. Chang, M. Leonido-Yee, et al. 2000. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 54: 1344-1349.
63. Nordahl, T.E., R. Salo, K. Possin, et al. 2002. Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetaminedependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy. Psychiatry Res. 116: 43-52.
64. Nordahl, T.E., R. Salo, Y.Natsuaki, et al. 2005.Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry 62: 444-452.
65. Salo, R., T.E. Nordahl, Y. Natsuaki, et al. 2007. Attentional control and brain metabolite levels in methamphetamine abusers. Biol. Psychiatry 61: 1272-1280.
66. Sung, Y.H., S.C. Cho, J. Hwang, et al. 2007. Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend. 88: 28-35.
67. Sekine, Y., Y. Minabe, M. Kawai, et al. 2002. Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology 27: 453-461.
68. Nash, J.F. & B.K. Yamamoto. 1992. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581: 237-243.
69. Yamamoto, B.K. & M.G. Bankson. 2005. Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit. Rev. Neurobiol. 17: 87-118.
70. Baker, D.A., K.McFarland, R.W. Lake, et al. 2003. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat. Neurosci. 6: 743-749.
71. LaRowe, S.D., H. Myrick, S. Hedden, et al. 2007. Is cocaine desire reduced by N-acetylcysteine? Am. J. Psychiatry 164: 1115-1117.
72. Mardikian, P.N., S.D. LaRowe, S. Hedden, et al. 2007. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 31: 389-394.
73. Gouzoulis-Mayfrank, E. & J. Daumann. 2006. Neurotoxicity ofmethylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 101: 348-361.
74. Creighton, F.J., D.L. Black & C.E. Hyde. 1991. 'Ecstasy' psychosis and flashbacks.Br. J. Psychiatry 159: 713-715.
75. Fetter, J.C. 2005. Mirtazepine for MDMA-induced depression. Am. J. Addict. 14: 300-301.
76. Pallanti, S. & D.Mazzi. 1992. MDMA (Ecstasy) precipitation of panic disorder. Biol. Psychiatry 32: 91-95.
77. Soar, K., A.C. Parrott & H.C. Fox. 2004. Persistent neuropsychological problems after 7 years of abstinence from recreational Ecstasty (MDMA): a case study. Psychol. Rep. 95: 192-196.
78. McCann, U.D., S.C. Peterson & G.A. Ricaurte. 2007. The effect of catecholamine depletion by alpha-methylpara- tyrosine on measures of cognitive performance and sleep in abstinentMDMA users. Neuropsychopharmacology 32: 1695-1706.
79. Reneman, L., C.B. Majoie, B. Schmand, et al. 2001. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol. Psychiatry 50: 550-554.
80. Reneman, L., C.B. Majoie, H. Flick, et al. 2002. Reduced N-acetylaspartate levels in the frontal cortex of 3,4- methylenedioxymethamphetamine (Ecstasy) users: preliminary results. AJNR Am. J. Neuroradiol. 23: 231-237.
81. Daumann, J., T. Fischermann, U. Pilatus, et al. 2004. Proton magnetic resonance spectroscopy in ecstasy (MDMA) users. Neurosci. Lett. 362: 113-116.
82. Chang, L., T. Ernst, C.S. Grob, et al. 1999. Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. J. Magn. Reson. Imaging 10: 521-526.
83. Cowan, R.L. 2007. Neuroimaging research in human MDMA users: a review. Psychopharmacology 189: 539-556.
84. Cowan, R.L., J.M. Joers & M.S. Dietrich. 2009. N-acetylaspartate (NAA) correlates inversely with cannabis use in a frontal language processing region of neocortex in MDMA (Ecstasy) polydrug users: a 3 T magnetic resonance spectroscopy study. Pharmacol. Biochem. Behav. 92: 105-110.
85. de Win, M.M., L. Reneman, G. Jager, et al. 2007. A prospective cohort study on sustained effects of lowdose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology 32: 458-470. (Pubitemid 46106952)
86. de Win, M.M., G. Jager, J. Booij, et al. 2008. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131(Pt 11): 2936-2945.
87. deWin, M.M., G. Jager, J. Booij, et al. 2008. Neurotoxic effects of ecstasy on the thalamus. Br. J. Psychiatry 193: 289-296.
88. Cowan, R.L., N.R. Bolo, M. Dietrich, et al. 2007. Occipital cortical proton MRS at 4 Tesla in human moderateMDMA polydrug users. Psychiatry Res. 155: 179-188.
89. Obergriesser, T., G. Ende, D.F. Braus, et al. 2001. Hippocampal 1H-MRSI in ecstasy users. Eur. Arch. Psychiatry Clin. Neurosci. 251: 114-116.
90. Gouzoulis-Mayfrank, E. & J. Daumann. 2006. The confounding problem of polydrug use in recreational ecstasy/ MDMA users: a brief overview. J. Psychopharmacol. 20: 188-193.
91. Meyer, J.S.,M.E. Brevard, B.J. Piper, et al. 2006. Neural effects of MDMA as determined by functional magnetic resonance imaging and magnetic resonance spectroscopy in awake marmosetmonkeys. Ann. N. Y. Acad. Sci. 1074: 365-376.
92. McCardle, K., S. Luebbers, J.D. Carter, et al. 2004. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 173: 434-439.
93. Kaufman, M.J., J.M. Levin, M.H. Ross, et al. 1998. Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA 279: 376-380.
94. Du, C., M. Yu, N.D. Volkow, et al. 2006. Cocaine increases the intracellular calcium concentration in brain independently of its cerebrovascular effects. J.Neurosci. 26: 11522-11531.
95. Meldrum, B.S. 1986. Cell damage in epilepsy and the role of calcium in cytotoxicity. Adv. Neurol. 44: 849-855.
96. Schanne, F.A., A.B. Kane, E.E. Young, et al. 1979. Calcium dependence of toxic cell death: a final common pathway. Science 206: 700-702.
97. Chang, L., T. Ernst, T. Strickland, et al. 1999. Gender effects on persistent cerebral metabolite changes in the frontal lobes of abstinent cocaine users. Am. J. Psychiatry 156: 716-722.
98. Chang,L., C.M.Mehringer, T. Ernst, et al. 1997.Neurochemical alterations in asymptomatic abstinent cocaine users: a proton magnetic resonance spectroscopy study. Biol. Psychiatry 42: 1105-1114.
99. Ke, Y., C.C. Streeter, L.E. Nassar, et al. 2004. Frontal lobe GABA levels in cocaine dependence: a twodimensional, J-resolved magnetic resonance spectroscopy study. Psychiatry Res. 130: 283-293.
100. Cendes, F., F. Andermann, F. Dubeau, et al. 1997. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from protonMRspectroscopic imaging.Neurology 49: 1525-1533
101. De Stefano, N., P.M. Matthews & D.L. Arnold. 1995. Reversible decreases in N- acetylaspartate after acute brain injury. Magn. Reson. Med. 34: 721-727.
102. Fein, G., V. Di Sclafani & D.J. Meyerhoff. 2002. Prefrontal cortical volume reduction associated with frontal cortex function deficit in 6-week abstinent crack-cocaine dependent men. Drug Alcohol Depend. 68: 87-93.
103. Matochik, J.A., E.D. London, D.A. Eldreth, et al. 2003. Frontal cortical tissue composition in abstinent cocaine abusers: a magnetic resonance imaging study.Neuroimage 19: 1095-1102.
104. Sim, M.E., I.K. Lyoo, C.C. Streeter, et al. 2007. Cerebellar gray matter volume correlates with duration of cocaine use in cocaine-dependent subjects. Neuropsychopharmacology 32: 2229-2237.
105. Li, S.-J., Y. Wang, R. Risinger, et al. 1998. Acute cocaine administration induces NAA increase detected by 1H MRS. In Proc. Int. Soc. Magn. Reson. Med. 6: 1714.
106. Christensen, J.D, M.J. Kaufman, B. Frederick, et al. 2000. Proton magnetic resonance spectroscopy of human basal ganglia: response to cocaine administration. Biol. Psychiatry 48: 685-692.
107. Lien, R., O.P.Mishra, E. Graham, et al. 1994. Alteration of brain cell membrane function following cocaine exposure in the fetal guinea pig. Brain Res. 637: 249-254.
108. Hertz, L.,W.E. Code & E. Sykova. 1992. Ions, water and energy in brain cells: a synopsis of interrelations. Can. J. Physiol. Pharmacol. 70: S100-S106.
109. Olson, J., R. Sankar, D. Holtzman, et al. 1986. Energydependent volume regulation in primary cultured cerebral astrocytes. J. Cell. Physiol. 128: 209-215.
110. Li, B.S., H. Wang & O. Gonen. 2003. Metabolite ratios to assumed stable creatine levels may confound the quantification of proton brainMRspectroscopy.Magn. Reson. Imaging 21: 923-928.
111. Kaufman, M.J., J.M. Levin, L.C. Maas, et al. 2001. Cocaine-induced cerebral vasoconstriction differs as a function of sex and menstrual cycle phase. Biol. Psychiatry 49: 774-781.
112. Hetherington, H.P., J.W. Pan, F. Telang, et al. 2000. Reduced brain GABA levels in cocaine abusers. In Proc. Int. Soc. Magn. Reson. Med. 8: 523.
113. Aron, J.L. & M.P. Paulus. 2007. Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. Addiction 102: 33-43.
114. Preti, A. 2007.Newdevelopments in the pharmacotherapy of cocaine abuse. Addict. Biol. 12: 133-151.
115. Gruber, S.A., M.M. Silveri, D.A. Yurgelun-Todd. 2007. Neuropsychological consequences of opiate use. Neuropsychol. Rev. 17: 299-315.
116. Wise, R.A. & M.A. Bozarth. 1982. Action of drugs of abuse on brain reward systems: an update with specific attention to opiates. Pharmacol. Biochem. Behav. 17: 239-243.
117. Ersche, K.D., P.C. Fletcher, S.J.G. Lewis, et al. 2005. Abnormal frontal activations related to decision making in current and former amphetamine and opiate dependent individuals. Psychopharmacology 180: 612-623.
118. Forman, S.D., G.G. Dougherty, B.J. Casey, et al. 2004. Opiate addicts lack error- dependent activation of rostral anterior cingulate. Biol. Psychiatry 55: 531-537.
119. Yücel, M., D.I. Lubman, B.J. Harrison, et al. 2007. A combined spectroscopic and functional MRI investigation of the dorsal anterior cingulate region in opiate addiction. Mol. Psychiatry 12: 611, 691-702.
120. Danos, P., S. Kasper, F. Grünwald, et al. 1998. Pathological regional cerebral blood flow in opiate-dependent patients during withdrawal: a HMPAO-SPECT study. Neuropsychobiology 37: 194-199.
121. Galynker, I.I., S. Watras-Ganz, C. Miner, et al. 2000. Cerebral metabolism in opiate-dependent subjects: effects of methadone maintenance. Mt. Sinai J. Med. 67: 381-387.
122. Krystal, J.H., S.W. Woods, T.R. Kosten, et al. 1995. Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). Am. J. Drug Alcohol Abuse 21: 47-63.
123. Rose, J.S., M. Branchey, L. Buydens-Branchey, et al. 1996. Cerebral perfusion deficits in early and late opiate withdrawal: a technetium-99m- HMPAOSPECT study. Psychiatry Res. 67: 39-47.
124. Lyoo, I.K., C.C. Streeter, K.H. Ahn, et al. 2004. White matter hyperintensities in subjects with cocaine and opiate dependence and healthy comparison subjects. Psychiatry Res. 131: 2229-2237.
125. Lyoo, I.K., M.H. Pollack, M.M. Silveri, et al. 2006. Prefrontal and temporal gray matter density decreases in opiate dependence. Psychopharmacology 184: 139-144.
126. Haselhorst, R., K.M. Dürsteler-MacFarland, K. Scheffler, et al. 2002. Frontocortical N-acetylaspartate reduction associated with long-term i.v. heroin use. Neurology 58: 305-307.
127. Kriegstein, A.R., D.C. Shungu, W.S. Millar, et al. 1999. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon"). Neurology 53: 1765-1773.
128. Offiah, C. & E. Hall. 2008. Heroin-induced leukoencephalopathy: characterization using MRI, diffusionweighted imaging, and MR spectroscopy. Clin. Radiol. 63: 146-152.
129. Mathews,P.M., F.Andermann, K. Silver, et al. 1993.ProtonMR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 43: 2484-2490.
130. Xiang, Y., H. Gao, H. Zhu, et al. 2006. Neurochemical changes in brain induced by chronic morphine treatment: NMR studies in thalamus and somatosensory cortex of rats. Neurochem. Res. 31: 1255-1261.
131. Murray, R.M., P.D. Morrison, C. Henquet, et al. 2007. Cannabis, the mind and society: the hash realities. Nat. Rev. Neurosci. 8: 885-895.
132. Chan, G.C., T.R. Hinds, S. Impey, et al. 1998. Hippocampal neurotoxicity of-9- tetrahydrocannabinol. J. Neurosci. 18: 5322-5332.
133. Landfield, P.W., L.B. Cadwallader & S. Vinsant. 1988. Quantitative changes in hippocampal structure following long-term exposure to delta 9- tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res. 443: 47-62.
134. Yücel, M., N. Solowij, C. Respondek, et al. 2008. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 65: 694-701.
135. Chang, L., C. Cloak, R. Yakupov, et al. 2006. Combined and independent effects of chronic marijuana use and HIV on brain metabolites. J. Neuroimmune Pharmacol. 1: 65-76.
136. Hermann, D., A. Sartorius, H.Welzel, et al. 2007. Dorsolateral prefrontal cortexN-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol. Psychiatry 61: 1281-1289.
137. Bertolino, A., D. Sciota, F. Brudaglio, et al. 2003.Working memory deficits and levels of N-acetylaspartate in patients with schizophreniformdisorder.Am. J. Psychiatry 160: 483-489.
138. Molina, V., J. Śanchez, S. Reig, et al. 2005. N-acetylaspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr. Res. 73: 209-219.
139. Henquet, C.,M.Di Forti, P.Morrison, et al. 2008. Geneenvironment interplay between cannabis andpsychosis. Schizophr. Bull. 34: 1111-1121.
140. Kril, J.J. & G.M. Halliday. 1999. Brain shrinkage in alcoholics: a decade on and what have we learned? Prog. Neurobiol. 58: 381-387.
141. Sullivan, E.V. 2000. Human brain vulnerability to alcoholism: evidence fromneuroimaging studies. In Review ofNIAAA'sNeuroscience and BehavioralResearch Portfolio (NIAAA ResearchMonograph No. 34). A. Noronha, M. Eckardt & K.Warren, Eds.: 473-508. National Institute on Alcohol Abuse and Alcoholism. Bethesda,MD.
142. Oscar-Berman,M. & K.Marinkovíc. 2007. Alcohol: effects on neurobehavioral functions and the brain. Neuropsychol. Rev. 17: 239-257.
143. Durazzo, T.C., S. Gazdzinski, P. Banys, et al. 2004. Cigarette smoking exacerbates chronic alcohol-induced brain damage: a preliminarymetabolite imaging study. Alcohol Clin. Exp. Res. 28: 1849-1860.
144. Jagannathan,N.R., N.G. Desai&P. Raghunathan. 1996. Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study. Magn. Reson. Imaging 14: 553-557.
145. Schweinsburg, B.C., M.J. Taylor, O.M. Alhassoon, et al. 2001. Chemical pathology in brain white matter of recently detoxified alcoholics: a 1H magnetic resonance spectroscopy investigation of alcohol-associated frontal lobe injury. Alcohol Clin. Exp. Res. 25: 924-934.
146. Schweinsburg, B.C., O.M. Alahassoon, M.J. Taylor, et al. 2003. Effects of alcoholism and gender on brain metabolism. Am. J. Psychiatry 160: 1180-1183.
147. Schweinsburg, B.C., M.J. Taylor, J.S. Videen, et al. 2000. Elevated myo-inositol in gray matter of recently detoxified but not long-term abstinent alcoholics: a preliminary MR spectroscopy study. Alcohol Clin. Exp. Res. 24: 699-705.
148. Seitz, D., U.Widmann, U. Seeger, et al. 1999. Localized proton magnetic resonance spectroscopy of the cerebellum in detoxifying alcoholics. Alcohol Clin. Exp. Res. 23: 158-163.
149. Lee, E., D.P. Jang, J.J. Kim, et al. 2007. Alteration of brain metabolites in young alcoholics without structural changes. Neuroreport 18: 1511-1514.
150. Miese, F.,G. Kircheis, H.J.Wittsack, et al. 2006. 1H-MR spectroscopy, magnetization transfer, and diffusionweighted imaging in alcoholic and nonalcoholic patientswith cirrhosiswith hepatic encephalopathy.AJNR Am. J. Neuroradiol. 27: 1019-1026.
151. Martin,P.R., S.J. Gibbs, A.A.Nimmerrichter, et al. 1995. Brain proton magnetic resonance spectroscopy studies in recently abstinent alcoholics. Alcohol Clin. Exp. Res. 19: 1078-1082.
152. O'Neill, J., V.A. Cardenas & D.J. Meyerhoff. 2001. Effects of abstinence on the brain: quantitative magnetic resonance imaging and magnetic resonance spectroscopic imaging in chronic alcohol abuse. Alcohol Clin. Exp. Res. 25: 1673-1682. (Pubitemid 33104930)
153. Meyerhoff, D.J., R. Blumenfeld, D. Truran, et al. 2004. Effects of heavy drinking, binge drinking, and family history of alcoholism on regional brain metabolites. Alcohol Clin. Exp. Res. 28: 650-661.
154. Gazdzinski, S., T.C. Durazzo,M.W.Weiner, et al. 2008a. Are treated alcoholics representative of the entire populationwith alcohol use disorders?Amagnetic resonance study of brain injury. Alcohol 42: 67-76.
155. Vengeliene, V., A. Bilbao, A.Molander, et al. 2008.Neuropharmacology of alcohol addiction. Br. J. Pharmacol. 154: 299-315.
156. Hoffman, P.L. & B. Tabakoff. 1996. Alcohol dependence: a commentary on mechanisms. Alcohol Alcohol. 31: 333-340.
157. Tsai, G.E., P. Ragan, R. Chang, et al. 1998. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am. J. Psychiatry 155: 726-732. (Pubitemid 28252650)
158. Behar, K.L., D.L. Rothman, K.F. Petersen, et al. 1999. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am. J. Psychiatry 156: 952-954.
159. Mason, G.F., I.L. Petrakis, R.A. de Graaf, et al. 2006. Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking. Biol. Psychiatry 59: 85-93.
160. Leshner, A.I. & G.F. Koob. 1999. Drugs of abuse and the brain. Proc. Assoc. Am. Physicians 111: 99-108.
161. Alexander, G.E.,M.D. Crutcher & M.R. DeLong. 1990. Basal ganglia-thalamo-cortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog. Brain Res. 85: 119-146.
162. Levin, E.D., F.J.McClernon&A.H.Rezvani. 2006.Nicotinic effectson cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 184: 523-539.
163. Gazdzinski, S., T.C. Durazzo, C. Studholme, et al. 2005. Quantitative brain MRI in alcohol dependence: preliminary evidence for effects of concurrent chronic cigarette smoking on regional brain volumes. Alcohol Clin. Exp. Res. 29: 1484-1495.
164. Brody, A.L.,M.A.Mandelkern, M.E. Jarvik, et al. 2004. Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol. Psychiatry 55: 77-84.
165. Gallinat, J., E. Meisenzahl, L.K. Jacobsen, et al. 2006. Smoking and structural brain deficits: a volumetricMR investigation. Eur. J. Neurosci. 24: 1744-1750.
166. Brody, A.L. 2006. Functional brain imaging of tobacco use and dependence. J. Psychiatr. Res. 40: 404-418.
167. Markou, A. 2008. Review. Neurobiology of nicotine dependence. Philos. Trans.R. Soc. Lond. B Biol. Sci. 363: 3159-3168.
168. Epperson, C.N., S. O'Malley, K.A. Czarkowski, et al. 2005. Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol. Psychiatry 57: 44-48.
169. Gallinat, J. & F. Schubert. 2007. Regional cerebral glutamate concentrations and chronic tobacco consumption. Pharmacopsychiatry 40: 64-67.
170. Gallinat, J.,U.E. Lang, L.K. Jacobsen, et al. 2007.Abnormal hippocampal neurochemistry in smokers: evidence from proton magnetic resonance spectroscopy at 3 T. J. Clin. Psychopharmacol. 27: 80-84.
171. Barros, D.M., F.G. Galhardi, J.L. Ribas Ferreira, et al. 2007. The benefits and drawbacks of nicotine exposure in the cortex and hippocampus of old rats.Neurotoxicity 28: 562-568.
172. Berger, F., F.H. Gage & S. Vijayaraghavan. 1998. Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J. Neurosci. 18: 6871-6881.
173. Trauth, J.A., F.J. Seidler, E.C.McCook, et al. 1999. Adolescent nicotine exposure causes persistent upregulation of nicotinic cholinergic receptors in rat brain regions. Brain Res. 851: 9-19.
174. Burling, T.A. & D.C. Ziff. 1988. Tobacco smoking: a comparison between alcohol and drug abuse inpatients. Addict. Behav. 13: 185-190.
175. DiFranza, J.R. & M.P. Guerrera. 1990. Alcoholism and smoking. J. Stud. Alcohol. 51: 130-135.
176. Littleton, J., S. Barron, M. Prendergast, et al. 2007. Smoking kills (alcoholics)! Shouldn't we do something about it? Alcohol Alcohol. 42: 167-173.
177. Gazdzinski, S., T.C. Durazzo, G.-H. Jahng, et al. 2006. Effects of chronic alcohol dependence and chronic cigarette smoking on cerebral perfusion: a preliminary magnetic resonance study. Alcohol Clin. Exp. Res. 30: 947-958.
178. Gazdzinski, S., T.C. Durazzo, P.H. Yeh, et al. 2008b. Chronic cigarette smokingmodulates injury and shorttermrecovery of themedial temporal lobe in alcoholics. Psychiatry Res. 162: 133-145.
179. Yücel, M., M. Takagi, M. Walterfang, et al. 2008. Toluene misuse and long- term harms: a systematic review of the neuropsychological and neuroimaging literature. Neurosci. Biobehav. Rev. 32: 910-926.
180. Gerasimov, M.R. 2004. Brain uptake and biodistribution of [11C]toluene in nonhuman primates and mice. Meth. Enzymol. 385: 334-349.
181. Gospe, S.M. Jr. & M.J. Calaban. 1988. Central nervous system distribution of inhaled toluene. Fundam. Appl. Toxicol. 11: 540-545.
182. Giedd, J.N. 2008. The teen brain: insights from neuroimaging. J. Adolesc. Health 42: 335-343.
183. Rosenberg, N.L., B.K. Kleinschmidt-DeMasters, K.A. Davis, et al. 1988. Toluene abuse causes diffuse central nervous system white matter changes. Ann. Neurol. 23: 611-614.
184. Aydin, K., S. Sencer, T. Demir, et al. 2002. Cranial MR findings in chronic toluene abuse by inhalation. AJNR Am. J. Neuroradiol. 23: 1173-1179.
185. Filley, C.M., R.K. Heaton & N.L. Rosenberg. 1990. White matter dementia in chronic toluene abuse. Neurology 40: 532-534.
186. Yamanouchi, N., S. Okada, K. Kodama, et al. 1997. Effects of MRI abnormalities on WAIS-R performance in solvent abusers. Acta Neurol. Scand. 96: 34-39.
187. Ikeda, M. & H. Tsukagoshi. 1990. Encephalopathy due to toluene sniffing. Report of a case with magnetic resonance imaging. Eur. Neurol. 30: 347-349.
188. Lubman,D.I., M. Yücel&A.J. Lawrence. 2008. Inhalant abuse among adolescents: neurobiological considerations. Br. J. Pharmacol. 154: 316-326.
189. Rosenberg, N.L., J. Grigsby, J. Dreisbach, et al. 2002. Neuropsychologic impairment and MRI abnormalities associated with chronic solvent abuse. J. Toxicol. Clin. Toxicol. 41: 209-210.
190. Zur, J. &W. Yule. 1990. Chronic solvent abuse. 1. Cognitive sequelae. Child Care Health Dev. 16: 1-20. (Pubitemid 20129123)
191. Stengard, K. 1994. Effects of toluene inhalation on extracellular striatal acetylcholine release studiedwith microdialysis. Pharmacol. Toxicol. 75: 115-118.
192. Gerasimov, M.R., W.K. Schiffer, D. Marstellar, et al. 2002. Toluene inhalation produces regionally specific changes in extracellular dopamine. Drug Alcohol Depend. 65: 243-251.
193. Riegel, A.C., A. Zapata, T.S. Shippenberg, et al. 2007. The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. Neuropsychopharmacology 32: 1558-1569.
194. Stengard, K., R. Tham, W.T. O'Connor, et al. 1993. Acute toluene exposure increases extracellularGABA in the cerebellumof rat: a microdialysis study. Pharmacol. Toxicol. 73: 315-318.
195. Win-Shwe, T.T., D. Mitsushima, D. Nakajima, et al. 2007. Toluene induces rapid and reversible rise of hippocampal glutamate and taurine neurotransmitter levels in mice. Toxicol. Lett. 168: 75-82.
196. Noda, S., N. Yamanouchi, S. Okada, et al. 1996. Proton MR spectroscopy in solvent abusers. Ann. N. Y. Acad. Sci. 801: 441-444.
197. Aydin, K., S. Sencer, K. Ogel, et al. 2003. Single-voxel protonMRspectroscopy in toluene abuse.Magn.Reson. Imaging 21: 777-785.
198. Ladefoged, O., P. Strange, A. Møller, et al. 1991. Irreversible effects in rats of toluene (inhalation) exposure for six months. Pharmacol. Toxicol. 68: 384-390.
199. Escobar, A. & C. Aruffo. 1980. Chronic thinner intoxication: clinicopathologic report of a human case. J. Neurol. Neurosurg. Psychiatry 43: 986-994.
200. Baydas, G., R.J. Reiter, V.S. Nedzvetskii, et al. 2003. Melatonin protects the central nervous system of rats against toluene-containing thinner intoxication by reducing reactive gliosis. Toxicol. Lett. 137: 169-174.
201. Huang, J., N. Asaeda, Y. Takeuchi, et al. 1992. Dose dependent effects of chronic exposure to toluene on neuronal and glial cell marker proteins in the central nervous system of rats. Br. J. Ind. Med. 49: 282-286.
202. Gotohda, T., I. Tokunaga, S. Kubo, et al. 2000. Effect of toluene inhalation on astrocytes and neurotrophic factor in rat brain. Forensic Sci. Int. 113: 233-238.
203. Takebayashi, K., Y. Sekine, N.Takei, et al. 2004.Metabolite alterations in basal ganglia associated with psychiatric symptoms of abstinent toluene users: a proton MRS study. Neuropsychopharmacology 29: 1019-1026.
204. Ertugrul, A. & B. Uluǧ. 2007. The effect of clozapine on neuroimaging findings in schizophrenia. Psychiatr. Danub. 19: 367-369.
205. Pedata, F., S. Sorbi & G. Pepeu. 2006. Choline highaffinity uptake andmetabolism andcholine acetyltransferase activity in the striatum of rats chronically treated with neuroleptics. J. Neurochem. 35: 606-611.
206. Bustillo, J.R., L.M. Rowland, J. Lauriello, et al. 2002. High choline concentrations in the caudate nucleus in antipsychotic-näve patients with schizophrenia. Am. J. Psychiatry 159: 130-133.
207. Di Costanzo, A., F. Trojsi,M. Tosetti, et al. 2003. Highfield proton MRS of human brain. Eur. J. Radiol. 48: 146-153.
208. Sawrie, S.M., R.C. Martin, R. Knowlton, et al. 2001. Relationships among hippocampal volumetry, proton magnetic resonance spectroscopy, and verbal memory in temporal lobe epilepsy. Epilepsia 42: 1403-1407. (Pubitemid 33140615)
209. Grachev, I.D., R. Kumar, T.S. Ramachandran, et al. 2001.Cognitive interference is associatedwith neuronal marker N-acetyl aspartate in the anterior cingulate cortex: an in vivo (1)H-MRS study of the Stroop Color- Word task. Mol. Psychiatry 6: 529-539.
210. Ohrmann, P., A. Siegmund, T. Suslow, et al. 2007. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-näve and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J. Psychiatry Res. 41: 625-634.
211. Field, M. &W.M. Cox. 2008. Attentional bias in addictive behaviors: a review of its development, causes, and consequences. Drug Alcohol Depend. 97: 1-20.
212. Robbins, T.W., K.D. Ersche & B.J. Everitt. 2008. Drug addiction and the memory systems of the brain. Ann. N. Y. Acad. Sci. 1141: 1-21.
213. Lin, A., B.D. Ross, K. Harris, et al. 2005. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2: 197-214.
214. Kushner, S.A., S.L. Dewey & C. Kornetsky. 1999. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 290: 797-802.
215. Stromberg, M., S. Mackler, J. Volpecelli, et al. 2001. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol. Biochem. Behav. 68: 291-299.
216. Brebner, K., A. Childress & D. Roberts. 2002. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol. 37: 478-484.
217. Gonzalez, G., K. Sevarino, M. Sofuoglu, et al. 2003. Tiagabine increases cocaine-free urines in cocainedependentmethadone- treated patients: results of a randomized pilot study. Addiction 98: 1625-1632.
218. Kampman, K.M., H. Pettinati, K.G. Lynch, et al. 2004. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 75: 233-240.
219. Winhusen, T.M., E.C. Somoza, J.M. Harrer, et al. 2005. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 100(Suppl. 1): 68-77.
220. Kreis, R., T. Ernst & B.D. Ross. 1993. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn. Reson. Med. 30: 424-437.
221. Pouwels, P.J., K. Brockmann, B. Kruse, et al. 1999. Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatr. Res. 46: 474-485.
222. Smith, L.M., L.Chang,M.L.Yonekura, et al. 2001.Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero. Neurology 57: 255-260. (Pubitemid 32667358)
223. Goodman, A. 2008. Neurobiology of addiction. An integrative review. Biochem. Pharmacol. 75: 266-322.
224. Murphy, E.J., B. Rajagopalan, K.M. Brindle, et al. 1989. Phospholipid bilayer contribution to 31PNMR spectra in vivo. Magn. Reson. Med. 12: 282-289.
225. Pettegrew, J., S. Kopp, N.Minshew, et al. 1987. 31PNuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: preliminary observations. J. Neuropath. Exp. Neurol. 46: 419-430.
226. Christensen, J.D.,M.J. Kaufman, J.M. Levin, et al. 1996. Abnormal cerebral metabolism in polydrug abusers during early withdrawal: a 31P MR spectroscopy study. Magn. Reson. Med. 35: 658-663.
227. MacKay, S., D.J.Meyerhoff,W.P. Dillon, et al. 1993. Alteration of brain phospholipid metabolites in cocainedependent polysubstance abusers. Biol. Psychiatry 34: 261-264.
228. Kaufman, M.J., M.H. Pollack, R.A. Villafuerte, et al. 1999. Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance. Psychiatry Res. 90: 143-152.
229. Silveri, M.M.,M.H. Pollack, C.I.Diaz, et al. 2004. Cerebral phosphorus metabolite and transverse relaxation time abnormalities in heroin-dependent subjects at onset of methadone maintenance treatment. Psychiatry Res. 131: 217-226.
230. deGraaf,R.A., G.F.Mason, A.B.Patel, et al. 2003. Invivo 1H-[13C]-NMR spectroscopy of cerebral metabolism. NMR Biomed. 16: 339-357.
231. Magistretti, P.J., L. Pellerin, D.L. Rothman, et al. 1999. Energy on demand. Science 283: 496-497.
232. Mason, G.F., R. Gruetter, D.L. Rothman, et al. 1995. Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J. Cereb. Blood Flow Metab. 15: 12-25.
233. Sibson, N.R., A. Dhankhar, G.F. Mason, et al. 1998. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc. Natl. Acad. Sci. USA 95: 316-321.
234. Mason, G.F. & J.H. Krystal. 2006. MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases. NMR Biomed. 19: 690-701.
235. Neale, J. & M. Robertson. 2003. Comparisons of selfreport data and oral fluid testing in detecting drug use amongst new treatment clients. Drug Alcohol Depend. 71: 57-64.
236. Baggot,M., B. Heifets, R.T. Jones, et al. 2000. Chemical analysis of ecstasy pills. JAMA 284: 2190.
237. Nahas, G.G. 1990. The experimental use of cocaine in human subjects. Bull. Narc. 42: 57-62.
238. Capizzano, A.A., R.E. Jorge, L.C. Acion, et al. 2007. In vivo proton magnetic resonance spectroscopy in patients with mood disorders: a technically oriented review. J. Magn. Reson. Imaging 26: 1378-1389.
239. Frahm, J., T. Michaelis, M. Klaus-Dietmar, et al. 1989. Localized NMR spectroscopy in vivo. NMR Biomed. 2: 188-195.
240. De Stefano, N.,M. Filippi, D.Miller, et al. 2007. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 69: 1942-1952.
241. Hsu, Y.-Y., C. Chang, C.-N. Chang, et al. 1999. Proton MR spectroscopy in patients with complex partial seizures: single-voxel spectroscopy versus chemicalshift imaging. AJNR Am. J. Neuroradiol. 20: 643-651.
242. Valette, J., M. Chaumeil, M. Guillermier, et al. 2008. Diffusion-weighted NMR spectroscopy allows probing of 13C labeling of glutamate inside distinct metabolic compartments in the brain.Magn. Reson.Med. 60: 306-311.
243. Licata, S.C., J.E. Jensen, D.M. Penetar, et al. 2009. A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4 Tesla. Psychopharmacology 203: 819-829.